A phase III, randomized, double-blind trial of platinum doublet chemotherapy +/-pembrolizumab (MK-3475) as neoadjuvant/adjuvant therapy for participants with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer (NSCLC) (KEYNOTE-671). NCT03425643

A randomized, double-blind, phase III study of platinum+pemetrexed chemotherapy with or without pembrolizumab (MK-3475) in first line metastatic non-squamous non-small cell lung cancer subjects (KEYNOTE-189). NCT02578680

Antonia SJ et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018;379(24):2342-50. Abstract

Antonia SJ et al. Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. N Engl J Med 2017;377(20):1919-29. Abstract

Brahmer JR et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018;36(17):1714-68. Abstract

Chen HHW; Kuo MT. Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget 2017;8(37):62742-58. Abstract

Cho JH et al. An open-label, multicenter, phase II single arm trial of osimertinib in NSCLC patients with uncommon EGFR mutation (KCSG-LU15-09). Proc WCLC 2018;Abstract OA10.05.

Forde PM et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 2018;378(21):1976-86. Abstract

Gallant JN et al. EGFR kinase domain duplication (EGFR-KDD) is a novel oncogenic driver in lung cancer that is clinically responsive to afatinib. Cancer Discov 2015;5(11):1155-63. Abstract

Gandhi L et al. Pembrolizumab plus chemotherapy in metastatic non-small cell lung cancer. N Engl J Med 2018;378(22):2078-92. Abstract

Heymach J et al. A phase II trial of poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC). Proc WCLC 2018;Abstract OA02.06.

Hude I et al. The emerging role of immune checkpoint inhibition in malignant lymphoma. Haematologica 2017;102(1):30-42. Abstract

Janne PA et al. Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. ASCO 2019;Abstract 9007.

Jotte RM et al. IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. ASCO 2018;Abstract LBA9000.

Konduri K et al. EGFR fusions as novel therapeutic targets in lung cancer. Cancer Discov 2016;6(6):601-11. Abstract

Lopes G et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. ASCO 2018;Abstract LBA4.

Manegold C et al. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J Thorac Oncol 2017;12(2):194-207. Abstract

Myung-Ju A et al. Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases. ASCO 2017;Abstract 2006.

Odegaard JI et al. Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies. Clin Cancer Res 2018;24(15):3539-49. Abstract

Papadimitrakopoulou VA et al. IMpower132: PFS and safety results with 1L atezolizumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. Proc WCLC 2018;Abstract OA05.07.

Paz-Ares L et al. Pembrolizumab plus chemotherapy for squamous non-small cell lung cancer. N Engl J Med 2018;379(21):2040-51. Abstract

Planchard D et al. Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes. Proc ELCC 2018;Abstract 128O.

Ramalingam SS et al. Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. Proc ESMO 2018;Abstract LBA50.

Reck M et al. Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 2019;37(7):537-46. Abstract

Reck M et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small cell lung cancer. N Engl J Med 2016;375(19):1823-33. Abstract

Reungwetwattana T et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small cell lung cancer. J Clin Oncol 2018;[Epub ahead of print]. Abstract

Socinski MA et al. Atezolizumab for first-line treatment of metastatic non-squamous NSCLC. N Engl J Med 2018;378(24):2288-301. Abstract

Soria JC et al. Osimertinib in untreated EGFR-mutated advanced non-small cell lung cancer. N Engl J Med 2018;378(2):113-25. Abstract

West H et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-small cell lung cancer (IMpower130): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019;20(7):924-37. Abstract

Wu YL et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small cell lung cancer and EGFR-activating mutations. J Clin Oncol 2018;36(26):2702-9. Abstract